{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:49:28Z","timestamp":1790660968080,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In March 2021, the U.S. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (r\/r FL) after at least 2 lines of systemic therapy. Approval was based on ZUMA-5, a single-arm, open-label, multicenter trial that evaluated a single infusion of axicabtagene ciloleucel, preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine, in this population. Efficacy was based on objective response rate (ORR) and duration of response (DOR) as determined by an independent review committee. Among 81 patients in the primary efficacy analysis, having a median of 3 (range 2-9) prior lines of systemic therapy, the ORR was 91% (95% confidence interval [CI]: 83-96) with a complete remission (CR) rate of 60% and a median time-to-response of 1 month. The median DOR was not reached, and the 1-year rate of continued remission was 76% (95% CI: 64-85). For all leukapheresed patients with FL in this trial (n = 123), the ORR was 89% (95% CI: 83-94) with a CR rate of 62%. Among 146 patients with indolent lymphoma evaluated for safety, cytokine release syndrome occurred in 84% (Grade \u22653, 8%) and neurological toxicities occurred in 77% (Grade \u22653, 21%), leading to implementation of a risk evaluation and mitigation strategy. Serious adverse reactions occurred in 48%. Post-marketing studies will further evaluate clinical benefit in patients with r\/r FL and long-term safety.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac054","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T04:16:48Z","timestamp":1645589808000},"page":"587-594","source":"Crossref","is-referenced-by-count":29,"title":["FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6941","authenticated-orcid":false,"given":"Najat","family":"Bouchkouj","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette L","family":"Kasamon","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Dai","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Theoret","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"},{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejashri","family":"Purohit-Sheth","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"George","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"2022070520264096200_CIT0001","author":"Zelenetz","year":"2021"},{"key":"2022070520264096200_CIT0002","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022070520264096200_CIT0003","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"2022070520264096200_CIT0004","doi-asserted-by":"crossref","first-page":"abstract 7513","DOI":"10.1200\/JCO.2019.37.15_suppl.7513","article-title":"MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Andorsky","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022070520264096200_CIT0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"2022070520264096200_CIT0006","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/bcp.13974","article-title":"Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study","volume":"85","author":"Gibiansky","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2022070520264096200_CIT0007","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022070520264096200_CIT0008","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"key":"2022070520264096200_CIT0009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","article-title":"Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review","volume":"6","author":"Locke","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022070520264096200_CIT0010","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022070520264096200_CIT0011","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022070520264096200_CIT0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2022070520264096200_CIT0013","author":"Kite Pharma, Inc"},{"key":"2022070520264096200_CIT0014","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2014"},{"key":"2022070520264096200_CIT0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/587\/44418335\/oyac054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/587\/44418335\/oyac054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:20:24Z","timestamp":1700263224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/7\/587\/6566218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,11]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac054","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,11]]}}}